Ticker > Company >

Omkar Pharmachem share price

Omkar Pharmachem Ltd.

BSE: 532167 SECTOR: Pharmaceuticals & Drugs  4553   1   0

26.94
-0.84 (-3.02%)
BSE: 23 Oct 4:00 PM

Price Summary

Today's High

₹ 28.48

Today's Low

₹ 26.94

52 Week High

₹ 28.48

52 Week Low

₹ 20.75

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

27.17 Cr.

Enterprise Value

27.4 Cr.

No. of Shares

1.01 Cr.

P/E

142.24

P/B

2.93

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  9.2

CASH

0.07 Cr.

DEBT

0.3 Cr.

Promoter Holding

0.03 %

EPS (TTM)

₹  0.19

Sales Growth

0%

ROE

2.07 %

ROCE

2.94%

Profit Growth

-4.4 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0%
3 Year25.99%
5 Year∞%

Profit Growth

1 Year-4.4%
3 Year-5.12%
5 Year19.63%

ROE%

1 Year2.07%
3 Year2.12%
5 Year1.19%

ROCE %

1 Year2.94%
3 Year2.97%
5 Year1.38%

Debt/Equity

0.0328

Price to Cash Flow

91.91

Interest Cover Ratio

9.6575

CFO/PAT (5 Yr. Avg.)

1.09608875517112

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 0.03 0.00
Jun 2024 0.03 0.00
Mar 2024 0.03 0.00
Dec 2023 0.03 0.00
Sep 2023 0.03 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 25.9918138862491% for the Past 3 years.
  • The company has significantly decreased its debt by 0.3183 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 60.225 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.09608875517112.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.94391025641027.

 Limitations

  • The company has shown a poor profit growth of -5.1207366579242% for the Past 3 years.
  • Company has a poor ROE of 2.12408119476524% over the past 3 years.
  • Company has a poor ROCE of 2.96662761137567% over the past 3 years
  • The company has a low EBITDA margin of -57.259254074074% over the past 5 years.
  • The company is trading at a high PE of 142.24.
  • The company is trading at a high EV/EBITDA of 95.1387.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 0.14 0.14 0.14 0.14 0.14
Total Expenditure 0.09 0.04 0.07 0.06 0.09
Operating Profit 0.05 0.09 0.07 0.08 0.05
Other Income 0 0 0 0 0
Interest 0 0 0 0.03 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.05 0.09 0.07 0.05 0.05
Tax 0 0 0 0.06 0
Profit After Tax 0.05 0.09 0.07 -0.02 0.05
Adjusted EPS (Rs) 0.05 0.09 0.07 -0.02 0.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0.05 0.27 0.54 0.54 0.54
Total Expenditure 0.25 0.25 0.27 0.23 0.26
Operating Profit -0.2 0.02 0.27 0.31 0.28
Other Income 0 0 0 0 0
Interest 0.05 0.06 0.06 0.05 0.03
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.26 -0.04 0.21 0.26 0.25
Tax 0 -0.26 0.03 0.07 0.06
Net Profit -0.26 0.22 0.18 0.2 0.19
Adjusted EPS (Rs.) -0.26 0.22 0.18 0.2 0.19

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10.08 10.08 10.08 10.08 10.08
Total Reserves -1.64 -1.42 -1.24 -1.04 -0.85
Borrowings 0 0 0 0 0
Other N/C liabilities 0 -0.26 -0.23 -0.16 -0.1
Current liabilities 0.92 0.97 0.98 0.69 0.36
Total Liabilities 9.36 9.37 9.6 9.57 9.49
Assets
Net Block 0 0 0.01 0 0.01
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 9.3 9.3 9.3 9.3 9.3
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.06 0.07 0.29 0.26 0.18
Total Assets 9.36 9.37 9.6 9.57 9.49
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.26 -0.04 0.21 0.26 0.25
Adjustment 0.05 0.06 0.06 0.05 0.03
Changes in Assets & Liabilities -0.01 0 -0.07 -0.04 0.01
Tax Paid 0 0 0 0 0
Operating Cash Flow -0.21 0.02 0.2 0.28 0.3
Investing Cash Flow 0 0 -0.01 0 -0.01
Financing Cash Flow 0.24 -0.02 -0.03 -0.35 -0.35
Net Cash Flow 0.02 0 0.17 -0.08 -0.06

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 0.03 0.03 0.03 0.03 0.03
dipakkumar mulchandbhai v... 0.01 0.01 0.01 0.01 0.01
shah kirtikumar laxmichan... 0.02 0.02 0.02 0.02 0.02
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 99.97 99.97 99.97 99.97 99.97
ahsan ali khan 1.83 1.83 1.83 1.83 1.83
akshay saxena 1.98 1.98 1.98 1.98 1.98
anand sharma 1.54 1.54 1.54 1.54 1.54
arvind singh rathore 1.04 1.04 1.04 1.04 1.04
ashok kumar bhatia 1.49 1.49 1.49 1.49 1.49
ashok kumar tiwari 1.64 1.64 1.64 1.64 1.64
avtar singh - - 1.56 1.56 1.56
bhag singh 2.48 2.48 2.48 2.48 2.48
gujarat state financial c... 1.49 1.49 1.49 1.49 1.49
gyan kaur 1.63 1.63 1.63 1.63 1.63
har kishan singh 1.29 1.29 1.29 1.29 1.29
harvinder singh chadha 1.12 1.12 1.12 1.12 1.12
jagdish chand bhatia 1.29 1.29 1.29 1.29 1.29
jaspal singh 1.12 1.12 1.12 - 1.12
jitender singh 1.74 1.74 1.74 1.74 1.74
kailash nath singh 1.49 1.49 1.49 1.49 1.49
kimati kumar singh 1.63 1.63 1.63 1.63 1.63
kuldeep singh - - - 3.72 3.72
laiqu ahmad ansari - - - 1.49 1.49
manmeet chadha 1.56 1.56 1.56 1.56 1.56
manoj kumar singh 1.76 1.76 1.76 1.76 1.76
navneet kumar saxena 1.93 1.93 1.93 1.93 1.93
radheshyam yadav 1.74 1.74 1.74 1.74 1.74
resam singh 2.48 2.48 2.48 2.48 2.48
roshan lal 1.11 1.11 1.11 1.11 1.11
rupesh chauhan 1.59 1.59 1.59 1.59 1.59
sanjeev saxena 2.94 2.94 2.94 2.94 2.94
shailesh sharma 1.41 1.41 1.41 1.41 1.41
shilendra yadav 1.64 1.64 1.64 1.64 1.64
vijay sharma 1.40 1.40 1.40 1.40 1.40
jaspal singh . - - - 1.12 -
kuldeep singh 3.72 3.72 3.72 - -
laiqu ahmed ansari 1.49 1.49 1.49 - -
sukhdev singh sabharwal 1.12 1.12 - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Omkar Pharmachem Stock Price Analysis and Quick Research Report. Is Omkar Pharmachem an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Omkar Pharmachem and its performance over the period of time. Omkar Pharmachem stock price today is Rs 26.94.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Omkar Pharmachem cash from the operating activity was Rs 0.2956 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Omkar Pharmachem has a Debt to Equity ratio of 0.0328 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Omkar Pharmachem , the EPS growth was -4.4343 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Omkar Pharmachem has OPM of 52.4814814814815 % which is a good sign for profitability.
     
  • ROE: Omkar Pharmachem have a poor ROE of 2.0693 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Omkar Pharmachem is Rs 26.94. One can use valuation calculators of ticker to know if Omkar Pharmachem share price is undervalued or overvalued.
Last Updated on:
Brief about Omkar Pharmachem
X